Krilogy Financial LLC Takes $731,000 Position in AstraZeneca PLC $AZN

Krilogy Financial LLC acquired a new position in AstraZeneca PLC (NASDAQ:AZN) during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 9,003 shares of the company’s stock, valued at approximately $731,000.

Several other large investors have also bought and sold shares of the company. Brighton Jones LLC boosted its position in shares of AstraZeneca by 93.2% during the 4th quarter. Brighton Jones LLC now owns 5,782 shares of the company’s stock valued at $379,000 after purchasing an additional 2,789 shares in the last quarter. AQR Capital Management LLC lifted its stake in AstraZeneca by 45.3% during the first quarter. AQR Capital Management LLC now owns 37,501 shares of the company’s stock valued at $2,756,000 after purchasing an additional 11,690 shares during the last quarter. CWM LLC lifted its stake in AstraZeneca by 88.1% during the second quarter. CWM LLC now owns 18,973 shares of the company’s stock valued at $1,326,000 after purchasing an additional 8,886 shares during the last quarter. Yousif Capital Management LLC boosted its holdings in AstraZeneca by 9.0% during the second quarter. Yousif Capital Management LLC now owns 33,778 shares of the company’s stock worth $2,360,000 after buying an additional 2,780 shares in the last quarter. Finally, Mutual Advisors LLC increased its holdings in shares of AstraZeneca by 25.9% in the second quarter. Mutual Advisors LLC now owns 13,167 shares of the company’s stock valued at $957,000 after buying an additional 2,712 shares in the last quarter. Institutional investors own 20.35% of the company’s stock.

AstraZeneca Stock Performance

AZN stock opened at $205.47 on Friday. The firm has a 50 day simple moving average of $112.72 and a 200 day simple moving average of $92.82. AstraZeneca PLC has a 52 week low of $122.48 and a 52 week high of $206.71. The stock has a market cap of $318.66 billion, a P/E ratio of 68.26, a P/E/G ratio of 1.59 and a beta of 0.34. The company has a debt-to-equity ratio of 0.54, a quick ratio of 0.69 and a current ratio of 0.88.

AstraZeneca Dividend Announcement

The business also recently declared a dividend, which will be paid on Monday, March 23rd. Stockholders of record on Friday, February 20th will be issued a dividend of $1.595 per share. This represents a dividend yield of 165.0%. The ex-dividend date is Friday, February 20th. AstraZeneca’s payout ratio is currently 34.77%.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. Jefferies Financial Group initiated coverage on AstraZeneca in a research note on Monday, October 27th. They set a “buy” rating for the company. Morgan Stanley reiterated an “overweight” rating and issued a $103.00 price target on shares of AstraZeneca in a research report on Wednesday, December 3rd. Citigroup began coverage on AstraZeneca in a research note on Tuesday, January 27th. They issued a “buy” rating on the stock. HSBC reaffirmed a “buy” rating and set a $108.00 price objective on shares of AstraZeneca in a research note on Wednesday, December 10th. Finally, Barclays reissued an “overweight” rating on shares of AstraZeneca in a research report on Tuesday, January 6th. Nine equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $95.75.

AstraZeneca Company Profile

AstraZeneca is a global, science-led biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca’s operations span research and development, large-scale manufacturing, and commercial distribution, with a presence in developed and emerging markets worldwide.

The company focuses on several core therapy areas including oncology, cardiovascular, renal and metabolism (CVRM), respiratory and immunology, and rare diseases.